10x Genomics
297 hedge funds and large institutions have $1.42B invested in 10x Genomics in 2025 Q2 according to their latest regulatory filings, with 74 funds opening new positions, 112 increasing their positions, 74 reducing their positions, and 50 closing their positions.
71% more call options, than puts
Call options by funds: $4.44M | Put options by funds: $2.6M
51% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 74
48% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 50
43% more capital invested
Capital invested by funds: $996M → $1.42B (+$424M)
8% more funds holding
Funds holding: 274 → 297 (+23)
4.96% more ownership
Funds ownership: 105.41% → 110.37% (+5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$26.7M |
| 2 |
BlackRock
New York
|
+$25.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.2M |
| 4 |
QCM
Quantinno Capital Management
New York
|
+$13.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$62.4M |
| 2 |
Millennium Management
New York
|
-$22.7M |
| 3 |
DM
Deerfield Management
New York
|
-$13.6M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$11.3M |
TXG Hedge Fund Activity: Q2 2025 in Review
297 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2025, worth a combined $1.42B — up 43% from $996M a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new TXG positions and 50 closed out — a net gain of 24 holders — while 112 added to existing stakes and 74 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $26.7M. The largest seller was UBS AM, cutting an estimated $62.4M.
- 297 institutional investors held 10x Genomics (TXG) as of Q2 2025, up from 274 in Q1 2025.
- Funds reported $1.42B of 10x Genomics stock for Q2 2025, up 43% quarter-over-quarter.
- 74 funds opened new 10x Genomics positions in Q2 2025 and 50 closed out, a net change of +24 holders.
- The largest 10x Genomics buyer in Q2 2025 was AQR Capital Management, an estimated $26.7M added.
- The largest 10x Genomics seller in Q2 2025 was UBS AM, an estimated $62.4M sold.
Based on aggregated 13F filings for Q2 2025.